TED Ted Baker Plc

RNS Number:1013Q
Cantor Fitzgerald Europe
15 August 2005

                                                                        FORM 8.3

   DEALINGS BY PERSONS WHO OWN OR CONTROL 1% OR MORE OF ANY CLASS OF RELEVANT
                                    SECURITY

              (Rule 8.3 of The City Code on Takeovers and Mergers)


Name of purchaser/vendor *                      Cantor Fitzgerald Europe

Company dealt in                                Tepnel Life Sciences Plc

Relevant security dealt in                      Ordinary Shares

If a connected EFM, name of offeree/offeror     N/A
with which connected

If a connected EFM, nature of connection #      N/A

Date of dealing                                 12th August 2005



DEALINGS +


Amount bought                                   Price per unit (currency must
                                                be stated)

550,000                                         8.5


Amount sold                                     Price per unit (currency must 
                                                be stated)


Resultant total amount and percentage of the    2,450,000    1.15%
same relevant security owned or controlled


IS A SUPPLEMENTAL FORM 8 (DERIVATIVE)/FORM 8 (OPTION) ATTACHED?           YES


Date of disclosure                              15th August 2005

Contact name                                    Claire Swaby

Telephone number                                020 7894 7990


*    Specify the owner or controller in addition to the person dealing.  The
     naming of nominees or vehicle companies is insufficient.  In the case of
     disclosure of dealings by fund managers on behalf of discretionary clients, 
     the clients need not be named.

#    See the definition of "connected fund managers and principal traders" in 
     the Definitions Section of the Code.

+    If disclosing dealings/holdings in derivatives or options, please attach
     Supplemental Form 8 (Derivative) or Supplemental Form 8 (Option), as
     appropriate.

For details of the Code's dealing disclosure requirements, see Rule 8 and its
Notes which can be viewed on the Takeover Panel's website at
www.thetakeoverpanel.org.uk.



                         SUPPLEMENTAL FORM 8 (DERIVATIVE)

                        DEALINGS/HOLDINGS IN DERIVATIVES

  (This form should be attached to Form 8.1, Form 8.1(b)(ii), Form 8.2 or Form
                              8.3, as appropriate)


Description of all derivative         Cantor Fitzgerald Europe is the beneficial 
products disclosed on this form       owner of 2,450,000   Tepnel Life Sciences 
                                      PLC ordinary shares. These shares are held 
                                      to hedge Contract for Differences ("CFD").

                                      A Long CFD is a product where the client 
                                      to whom the product is sold is taking a 
                                      long economic interest in the underlying 
                                      share price such that the client can 
                                      realise a gain if the price of the 
                                      underlying securities rises above the 
                                      reference price.

                                      A purchaser of a CFD contract will realise 
                                      a gain if the price of the underlying 
                                      security goes up. A seller of a CFD 
                                      contract will realise a gain if the price 
                                      of the underlying security goes down.

Full details of any agreement, 
arrangement or understanding between 
the person disclosing and any other
person relating to the voting rights 
or future acquisition or disposal of 
any relevant securities to which any 
derivative referred to on this form 
is referenced.  If none, this should 
be stated.                            none


WRITING/ENTERING INTO A DERIVATIVE

Product name  Transaction  Writing/entering  Number of      Reference  Maturity 
eg long CFD   date         into (indicate    securities     price      date
                           as applicable)    to which the   (currency 
                                             derivative is  must be 
                                             referenced     stated)
Tepnel Life   
Sciences
Plc, Long CFD 12/08/05     Written           550,000        8.5


CLOSING OUT A DERIVATIVE

Product name  Transaction  Number of securities  Reference   Closing out price 
eg long CFD   date         to which the          price       (currency must be 
                           derivative is         (currency   stated)
                           referenced            must be
                                                 stated)


DETAILS OF OPEN DERIVATIVES (excluding any transaction set out above)

Product name  Transaction  Written/entered  Number of      Reference   Maturity 
eg long CFD   date         into (indicate   securities to  price       date
                           as applicable)   which the      (currency 
                                            derivative is  must be 
                                            referenced     stated)

Tepnel Life   19/07/05     Written          700,000        9.5
Sciences 
Plc, Long CFD 

Tepnel Life
Sciences
Plc, Long CFD 25/07/05     Written          1,000,000      9

Tepnel Life
Sciences
Plc, Long CFD 10/08/05     Written          200,000        9.5


For details of the Code's dealing disclosure requirements, see Rule 8 and its
Notes which can be viewed on the Takeover Panel's website at
www.thetakeoverpanel.org.uk.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
RETEADPSFEPSEFE

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024

Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024